Profile of omalizumab in the treatment of chronic spontaneous urticaria - Wikidata - awgldk - TriplyDB

Profile of omalizumab in the treatment of chronic spontaneous urticaria

Profile of omalizumab in the treatment of chronic spontaneous urticaria

http://www.wikidata.org/entity/Q26783158

about

Omalizumab therapy for treatment of recalcitrant chronic spontaneous urticaria in an Asian population.

P2860

Q39624099-405715C8-FE67-48C6-A1CF-538A3F6B90FF

P2860

Profile of omalizumab in the treatment of chronic spontaneous urticaria

http://www.wikidata.org/entity/Q26783158

description

2015 nî lūn-bûn

@nan

2015 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Profile of omalizumab in the treatment of chronic spontaneous urticaria

@ast

Profile of omalizumab in the treatment of chronic spontaneous urticaria

@en

Profile of omalizumab in the treatment of chronic spontaneous urticaria

@nl

type

label

Profile of omalizumab in the treatment of chronic spontaneous urticaria

@ast

Profile of omalizumab in the treatment of chronic spontaneous urticaria

@en

Profile of omalizumab in the treatment of chronic spontaneous urticaria

@nl

prefLabel

Profile of omalizumab in the treatment of chronic spontaneous urticaria

@ast

Profile of omalizumab in the treatment of chronic spontaneous urticaria

@en

Profile of omalizumab in the treatment of chronic spontaneous urticaria

@nl

P1433

Q26783158-CE7D29C9-AEE1-4DBF-B121-831837E22142

P1476

Q26783158-EFD08A67-A012-4F9D-B8F2-2D3F053E3F23

P2093

Q26783158-755FBC36-6B4F-4E8E-AEC0-8F6074E364E5

Q26783158-DC849839-2925-406E-AB24-9EA3061BC1F1

P275

Q26783158-9ADA7FB0-0FF4-4B2F-8838-5C7B814D4792

P2860

Q26783158-04344F0E-C8A4-4850-8668-C18A405BC347

Q26783158-13817EDD-DBD1-4D3E-9077-10BD1C5BA620

Q26783158-17658EBD-C0EA-4241-A299-B64B50213C6C

Q26783158-1A2E40F4-2CA3-40E4-B501-DAC7B5C379B7

Q26783158-1B8AD200-F240-42DE-91DB-254129C23D6A

Q26783158-1BAC6193-91AD-4704-82F0-2B2E2490510D

Q26783158-2A8F8629-F4B8-4527-AD37-B9A985207DD0

Q26783158-3105590E-0D9D-4231-B1B4-3A2AE34CBBEE

Q26783158-35A50D49-085B-49F3-9B4D-04A51E8FF035

Q26783158-42D408F3-5483-4E79-843E-6D1ACD192A62

P304

Q26783158-596A9710-4FDC-4EFA-B3C7-A16EB2694AF0

P31

Q26783158-1FF52C44-1ADD-4D6D-9E70-A34CA6EFD223

Q26783158-6B829301-0047-44C9-9397-89C39BE04948

P356

Q26783158-20E3A0F9-95F5-4562-AD74-947CD4AE633D

P407

Q26783158-654F0706-2721-4C57-8E60-D5C0B174C491

P478

Q26783158-1AFC5611-8B99-4ED4-B7C6-9AE36694EA90

P50

Q26783158-AC8721E7-5E56-4885-8B5E-9CD22DC91686

Q26783158-EC18A452-9608-4CA6-BACB-9F110D88CB72

P5008

Q26783158-5BDBF4D6-8D94-44A1-A357-E11A120CC82D

P577

Q26783158-B175107B-3B49-4B52-8BFD-2E7298ACD059

P5875

Q26783158-835B0ED8-C30F-496A-8701-FC4A9746C2D2

P698

Q26783158-C40C0160-D0D3-4554-863F-E11D1916D084

P921

Q26783158-1F679C63-772B-4B61-A4B8-6698623FD461

Q26783158-5B796864-81DB-4FC9-8744-523155A815C3

Q26783158-861DF72E-249E-4DD6-A867-53722491CEED

Q26783158-D96782A5-7E22-4C72-ACCF-C2CF67179B5A

Q26783158-FEBA74C1-6445-4F56-9050-793F979CEC7F

P932

Q26783158-FD82487F-9BB1-4E43-A35C-EC384AF84AA1

P356

P1433

Drug Design, Development and Therapy

P1476

Profile of omalizumab in the treatment of chronic spontaneous urticaria

@en

P2093

Marta Ferrer

http://www.w3.org/2001/XMLSchema#string

Moises Labrador-Horrillo

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution-NonCommercial

P2860

EAACI taskforce position paper: evidence for autoimmune urticaria and proposal for defining diagnostic criteria

Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria.

Blood basophil numbers in chronic ordinary urticaria and healthy controls: diurnal variation, influence of loratadine and prednisolone and relationship to disease activity.

A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine-refractory chronic idiopathic urticaria.

Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy.

Down-regulation of Fc(epsilon)RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody.

Treatment of chronic autoimmune urticaria with omalizumab.

Successful and Safe Treatment of Chronic Spontaneous Urticaria with Omalizumab in a Woman during Two Consecutive Pregnancies.

Omalizumab: Anti-IgE therapy in allergy.

Chronic spontaneous urticaria in children: itching for insight.

P304

4909-4915

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/DDDT.S56004

http://www.w3.org/2001/XMLSchema#string

P407

P478

9

http://www.w3.org/2001/XMLSchema#string

P50

Moises Labrador-Horrillo

P5008

P577

2015-08-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

281623161

http://www.w3.org/2001/XMLSchema#string

P698

26346472

http://www.w3.org/2001/XMLSchema#string

P921

monoclonal antibody

P932

4554406

http://www.w3.org/2001/XMLSchema#string